Patients with primary progressive MS who received the anti-CD20+ humanized antibody ocrelizumab were less likely to have clinical deterioration that was sustained for 12 weeks than those who received placebo. The drug was associated with decreased lesion activity on MRI.
- CME
- Comments
In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse rates, lower risk of disability progression, and better MRI features than interferon beta-1a.
This study from South Africa showed that extensively drug-resistant tuberculosis, an emerging global public health threat, is largely associated with transmission of drug-resistant strains rather than new emergence of drug resistance.
- Free Full Text
- Discussion
Related NEJM Group Open Forum on Medstro.com
A 62-year-old man with sarcoidosis and heart disease had new-onset diplopia and weakness. What is the most likely diagnosis?
Vote and comment. Find the answers in the full text of the case, to be published on January 26. On Twitter use #NEJMCases.
- Comments
- Poll
Eighteen patients in a street-drug–induced stupor were seen in EDs on a single day in a New York City neighborhood. With rapid cooperative efforts among physicians, police, public health authorities, and toxicologists, the cannabinoid AMB-FUBINACA was identified as the cause. (View Video.)
- Quick Take
In this case study, variant Creutzfeldt–Jakob disease (CJD) is shown to occur in a young man with heterozygosity, rather than homozygosity, at codon 129 of the prion protein gene (PRNP).
(DOI: 10.1056/NEJMp1613577)
(DOI: 10.1056/NEJMp1613861)
(DOI: 10.1056/NEJMp1613876)
Featured Multimedia
- CME
- Comments
- Quick Take
- Free Full Text
- CME
- Free Full Text
- CME
Perspective
- Free Full Text
- Audio Interview
- Comments
- Free Full Text
- No corrections published in this issue.
(DOI: 10.1056/NEJMp1613577)
(DOI: 10.1056/NEJMp1613861)
(DOI: 10.1056/NEJMp1613876)
(DOI: 10.1056/NEJMc1610614)
(DOI: 10.1056/NEJMp1616577)
